Journal article · 2021 · Open access

Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials

Richard Bruce Warren, Alice Bendix Gottlieb, Joseph Frank Merola, Llenalia Garcia, Christopher Cioffi, Luke Peterson, Christopher G. Pelligra, Valérie Ciaravino

Dermatology and Therapy, 11(5), 1551–1569 · Published 14 July 2021 · DOI 10.1007/s13555-021-00570-4

Open PDFView at the publisherCite this paper

In brief

“Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials” is a 2021 journal article by Richard Bruce Warren and 7 co-authors, published in Dermatology and Therapy. OpenAlex counts 12 citations as of 22 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Dermatology and Therapy.

Citations
12
Most cited in
2024 (5)
Field-weighted impact
0.83
References
34
Authors
8

Abstract

INTRODUCTION: Plaque psoriasis can significantly impact patients' quality of life. We assessed psychometric properties of the Psoriasis Symptoms and Impacts Measure (P-SIM), developed to capture patients' experiences of signs, symptoms and impacts of psoriasis. METHODS: Pooled, blinded, 16-week data from 1002 patients in the BE VIVID and BE READY bimekizumab phase 3 trials were analysed. The suitability of the P-SIM missing score rule (weekly scores considered missing if ≥ 4 daily scores were missing) was assessed. Test-retest reliability was evaluated using intraclass correlation coefficients (ICCs). Convergent validity was assessed between P-SIM and relevant patient-reported outcome (PRO) (Dermatology Life Quality Index [DLQI], DLQI item 1 [skin symptoms], Patient Global Assessment of Psoriasis) and clinician-reported outcome (ClinRO) scores (Psoriasis Area and Severity Index [PASI], Investigator's Global Assessment [IGA]) at baseline and week 16. Known-groups validity was assessed, comparing P-SIM scores between patient subgroups predefined using PASI/IGA scores. Sensitivity to change over 16 weeks was evaluated; responder definition (RD) thresholds were explored. RESULTS: The missing score rule used did not impact P-SIM scores. Test-retest reliability analyses demonstrated excellent score reproducibility (ICC 0.91-0.98). Inter-item correlations at baseline and week 16 were strong (> 0.5), apart from "choice of clothing" with "skin pain" and "burning" at baseline (both 0.49). All P-SIM scores were moderately to strongly correlated with other outcomes, demonstrating convergent validity, apart from ClinROs (PASI, IGA) at baseline that had low variability. P-SIM scores discriminated known groups at week 16, confirming known-groups validity. Changes from baseline to week 16 in P-SIM and other clinically relevant outcomes were strongly correlated (> 0.5; weaker with ClinROs), establishing sensitivity to change. Anchor-based RD analyses determined a four-point P-SIM item score decrease as indicative of marked clinically meaningful improvement. CONCLUSION: P-SIM scores demonstrated good reliability, validity and sensitivity to change. A four-point RD threshold could be used to assess 16-week treatment effects. TRIAL REGISTRATION: BE VIVID: NCT03370133; BE READY: NCT03410992.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Warren, R. B., Gottlieb, A. B., Merola, J. F., Garcia, L., Cioffi, C., Peterson, L., Pelligra, C. G., & Ciaravino, V. (2021). Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials. Dermatology and Therapy, 11(5), 1551–1569. https://doi.org/10.1007/s13555-021-00570-4

MLA 9

Warren, Richard Bruce, et al. “Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.” Dermatology and Therapy, vol. 11, no. 5, 2021, pp. 1551–1569. https://doi.org/10.1007/s13555-021-00570-4.

Chicago

Warren, Richard Bruce, Alice Bendix Gottlieb, Joseph Frank Merola, Llenalia Garcia, Christopher Cioffi, Luke Peterson, Christopher G. Pelligra, and Valérie Ciaravino. 2021. “Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.” Dermatology and Therapy 11 (5): 1551–1569. https://doi.org/10.1007/s13555-021-00570-4.

Harvard

Warren, R. B. et al. (2021) ‘Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials’, Dermatology and Therapy, 11(5), pp. 1551–1569. doi:10.1007/s13555-021-00570-4.

IEEE

R. B. Warren et al., “Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials,” Dermatology and Therapy, vol. 11, no. 5, pp. 1551–1569, 2021, doi: 10.1007/s13555-021-00570-4.

BibTeX

@article{warren2021psychometric,
  title     = {{Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials}},
  author    = {Warren, Richard Bruce and Gottlieb, Alice Bendix and Merola, Joseph Frank and Garcia, Llenalia and Cioffi, Christopher and Peterson, Luke and Pelligra, Christopher G. and Ciaravino, Valérie},
  journal   = {Dermatology and Therapy},
  year      = {2021},
  volume    = {11},
  number    = {5},
  pages     = {1551--1569},
  doi       = {10.1007/s13555-021-00570-4},
  url       = {https://doi.org/10.1007/s13555-021-00570-4}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202122
202211
202322
202455
202511
202611

Its field-weighted citation impact is 0.83: it has been cited 0.83 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis

  • plaque psoriasis
  • patient-reported outcomes
  • psychometric validation
  • bimekizumab
  • test-retest reliability
  • convergent validity
  • known-groups validity
  • sensitivity to change

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Warren, R. B., Gottlieb, A. B., Merola, J. F., Garcia, L., Cioffi, C., Peterson, L., Pelligra, C. G., & Ciaravino, V. (2021). Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials. Dermatology and Therapy, 11(5), 1551–1569. https://doi.org/10.1007/s13555-021-00570-4

How many times has this paper been cited?

12 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Dermatology and Therapy: sign in and open the PDF from this page.

Who wrote this paper?

Richard Bruce Warren, Alice Bendix Gottlieb, Joseph Frank Merola, Llenalia Garcia, Christopher Cioffi, Luke Peterson, Christopher G. Pelligra, Valérie Ciaravino.

What is the DOI of this paper?

10.1007/s13555-021-00570-4, permanently at https://doi.org/10.1007/s13555-021-00570-4. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.